Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 204

1.

The high cost of critical care unit over-utilization for patients with NSTE ACS.

van Diepen S, Tran DT, Ezekowitz JA, Zygun DA, Katz JN, Lopes RD, Newby LK, McAlister FA, Kaul P.

Am Heart J. 2018 May 19;202:84-88. doi: 10.1016/j.ahj.2018.05.003. [Epub ahead of print]

PMID:
29906667
2.

The Use of Biomarkers to Predict Specific Causes of Death in Patients with Atrial Fibrillation: Insights from the ARISTOTLE Trial.

Sharma A, Hijazi Z, Andersson U, Al-Khatib SM, Lopes RD, Alexander JH, Held C, Hylek EM, Leonardi S, Hanna M, Ezekowitz JA, Siegbahn A, Granger CB, Wallentin L.

Circulation. 2018 Jun 5. pii: CIRCULATIONAHA.118.034125. doi: 10.1161/CIRCULATIONAHA.118.034125. [Epub ahead of print]

PMID:
29871978
3.

Examining the Influence of Component Outcomes on the Composite at the Design Stage.

Brown PM, Ezekowitz JA.

Circ Cardiovasc Qual Outcomes. 2018 Jun;11(6):e004419. doi: 10.1161/CIRCOUTCOMES.117.004419. No abstract available.

PMID:
29860234
4.

Trends in Noncardiovascular Comorbidities Among Patients Hospitalized for Heart Failure: Insights From the Get With The Guidelines-Heart Failure Registry.

Sharma A, Zhao X, Hammill BG, Hernandez AF, Fonarow GC, Felker GM, Yancy CW, Heidenreich PA, Ezekowitz JA, DeVore AD.

Circ Heart Fail. 2018 Jun;11(6):e004646. doi: 10.1161/CIRCHEARTFAILURE.117.004646.

PMID:
29793934
5.

Implantable cardioverter-defibrillators in heart failure patients with reduced ejection fraction and diabetes.

Sharma A, Al-Khatib SM, Ezekowitz JA, Cooper LB, Fordyce CB, Michael Felker G, Bardy GH, Poole JE, Thomas Bigger J, Buxton AE, Moss AJ, Friedman DJ, Lee KL, Steinman R, Dorian P, Cappato R, Kadish AH, Kudenchuk PJ, Mark DB, Peterson ED, Inoue LYT, Sanders GD.

Eur J Heart Fail. 2018 Jun;20(6):1031-1038. doi: 10.1002/ejhf.1192. Epub 2018 May 15.

PMID:
29761861
6.

Reply to McClure et al.-Reader Commentary on 2017 Comprehensive Update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure.

Ezekowitz JA, McMurtry MS.

Can J Cardiol. 2018 Jun;34(6):813.e3. doi: 10.1016/j.cjca.2018.03.004. Epub 2018 Mar 16. No abstract available.

PMID:
29735318
7.

Ambulance use, distance and outcomes in patients with suspected cardiovascular disease: a registry-based geographic information system study.

Sepehrvand N, Alemayehu W, Kaul P, Pelletier R, Bello AK, Welsh RC, Armstrong PW, Ezekowitz JA.

Eur Heart J Acute Cardiovasc Care. 2018 Apr 1:2048872618769872. doi: 10.1177/2048872618769872. [Epub ahead of print]

PMID:
29652166
8.

Effects of supplemental oxygen therapy in patients with suspected acute myocardial infarction: a meta-analysis of randomised clinical trials.

Sepehrvand N, James SK, Stub D, Khoshnood A, Ezekowitz JA, Hofmann R.

Heart. 2018 Mar 29. pii: heartjnl-2018-313089. doi: 10.1136/heartjnl-2018-313089. [Epub ahead of print]

PMID:
29599378
9.

Is Time of the Essence? The Impact of Time of Hospital Presentation in Acute Heart Failure: Insights From ASCEND-HF Trial.

Cerbin LP, Ambrosy AP, Greene SJ, Armstrong PW, Butler J, Coles A, DeVore AD, Ezekowitz JA, Hernandez AF, Metra M, Starling RC, Tang W, Teerlink JR, Voors AA, Wu A, O'Connor CM, Mentz RJ.

JACC Heart Fail. 2018 Apr;6(4):298-307. doi: 10.1016/j.jchf.2018.01.018. Epub 2018 Mar 7.

PMID:
29525328
10.

Interaction of Body Mass Index on the Association Between N-Terminal-Pro-b-Type Natriuretic Peptide and Morbidity and Mortality in Patients With Acute Heart Failure: Findings From ASCEND-HF (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure).

Bhatt AS, Cooper LB, Ambrosy AP, Clare RM, Coles A, Joyce E, Krishnamoorthy A, Butler J, Felker GM, Ezekowitz JA, Armstrong PW, Hernandez AF, O'Connor CM, Mentz RJ.

J Am Heart Assoc. 2018 Feb 3;7(3). pii: e006740. doi: 10.1161/JAHA.117.006740.

11.

Use of Direct Oral Anticoagulants in Canadian Primary Care Practice 2010-2015: A Cohort Study From the Canadian Primary Care Sentinel Surveillance Network.

McAlister FA, Garrison S, Kosowan L, Ezekowitz JA, Singer A.

J Am Heart Assoc. 2018 Jan 26;7(3). pii: e007603. doi: 10.1161/JAHA.117.007603.

12.

Prediction of Early Adverse Events in Emergency Department Patients With Acute Heart Failure: A Systematic Review.

Michaud AM, Parker SIA, Ganshorn H, Ezekowitz JA, McRae AD.

Can J Cardiol. 2018 Feb;34(2):168-179. doi: 10.1016/j.cjca.2017.09.004. Epub 2017 Sep 12. Review.

PMID:
29287944
13.

Sudden cardiac death after acute heart failure hospital admission: insights from ASCEND-HF.

Pokorney SD, Al-Khatib SM, Sun JL, Schulte P, O'Connor CM, Teerlink JR, Armstrong PW, Ezekowitz JA, Starling RC, Voors AA, Velazquez EJ, Hernandez AF, Mentz RJ.

Eur J Heart Fail. 2018 Mar;20(3):525-532. doi: 10.1002/ejhf.1078. Epub 2017 Dec 20.

PMID:
29266564
14.

Impact of climate and air pollution on acute coronary syndromes: an update from the European Society of Cardiology Congress 2017.

Kaluzna-Oleksy M, Aunan K, Rao-Skirbekk S, Kjellstrom T, Ezekowitz JA, Agewall S, Atar D.

Scand Cardiovasc J. 2018 Feb;52(1):1-3. doi: 10.1080/14017431.2017.1405069. Epub 2017 Dec 4. No abstract available.

PMID:
29202608
15.

2017 Comprehensive Update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure.

Ezekowitz JA, O'Meara E, McDonald MA, Abrams H, Chan M, Ducharme A, Giannetti N, Grzeslo A, Hamilton PG, Heckman GA, Howlett JG, Koshman SL, Lepage S, McKelvie RS, Moe GW, Rajda M, Swiggum E, Virani SA, Zieroth S, Al-Hesayen A, Cohen-Solal A, D'Astous M, De S, Estrella-Holder E, Fremes S, Green L, Haddad H, Harkness K, Hernandez AF, Kouz S, LeBlanc MH, Masoudi FA, Ross HJ, Roussin A, Sussex B.

Can J Cardiol. 2017 Nov;33(11):1342-1433. doi: 10.1016/j.cjca.2017.08.022. Epub 2017 Sep 6.

PMID:
29111106
16.

Aetiology, timing and clinical predictors of early vs. late readmission following index hospitalization for acute heart failure: insights from ASCEND-HF.

Fudim M, O'Connor CM, Dunning A, Ambrosy AP, Armstrong PW, Coles A, Ezekowitz JA, Greene SJ, Metra M, Starling RC, Voors AA, Hernandez AF, Michael Felker G, Mentz RJ.

Eur J Heart Fail. 2018 Feb;20(2):304-314. doi: 10.1002/ejhf.1020. Epub 2017 Oct 29.

PMID:
29082629
17.

Relationship between baseline systolic blood pressure and long-term outcomes in acute heart failure patients treated with TRV027: an exploratory subgroup analysis of BLAST-AHF.

Cotter G, Davison BA, Butler J, Collins SP, Ezekowitz JA, Felker GM, Filippatos G, Levy PD, Metra M, Ponikowski P, Teerlink JR, Voors AA, Senger S, Bharucha D, Goin K, Soergel DG, Pang PS.

Clin Res Cardiol. 2018 Feb;107(2):170-181. doi: 10.1007/s00392-017-1168-0. Epub 2017 Oct 6.

PMID:
28986703
18.

Heart Failure in Young Adults Is Associated With High Mortality: A Contemporary Population-Level Analysis.

Wong CM, Hawkins NM, Ezekowitz JA, Jhund PS, Savu A, MacDonald MR, Kristensen SL, Petrie MC, McMurray JJV, McAlister FA, Kaul P.

Can J Cardiol. 2017 Nov;33(11):1472-1477. doi: 10.1016/j.cjca.2017.05.009. Epub 2017 Jun 19.

PMID:
28941947
19.

Ivabradine in Heart Failure: The Representativeness of SHIFT (Systolic Heart Failure Treatment With the IF Inhibitor Ivabradine Trial) in a Broad Population of Patients With Chronic Heart Failure.

Das D, Savarese G, Dahlström U, Fu M, Howlett J, Ezekowitz JA, Lund LH.

Circ Heart Fail. 2017 Sep;10(9). pii: e004112. doi: 10.1161/CIRCHEARTFAILURE.117.004112.

PMID:
28903983
20.

Letter by Kaul et al Regarding Article, "Age-Specific Trends in Incidence, Mortality, and Comorbidities of Heart Failure in Denmark, 1995 to 2012".

Kaul P, Ezekowitz JA, McAlister FA.

Circulation. 2017 Aug 29;136(9):884-885. doi: 10.1161/CIRCULATIONAHA.117.029335. No abstract available.

PMID:
28847802
21.

Effect of Natriuretic Peptide-Guided Therapy on Hospitalization or Cardiovascular Mortality in High-Risk Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.

Felker GM, Anstrom KJ, Adams KF, Ezekowitz JA, Fiuzat M, Houston-Miller N, Januzzi JL Jr, Mark DB, Piña IL, Passmore G, Whellan DJ, Yang H, Cooper LS, Leifer ES, Desvigne-Nickens P, O'Connor CM.

JAMA. 2017 Aug 22;318(8):713-720. doi: 10.1001/jama.2017.10565.

22.

A prospective evaluation of the established criteria for heart failure with preserved ejection fraction using the Alberta HEART cohort.

Ezekowitz JA, McAlister FA, Howlett J, Alemayehu W, Paterson I, Belenkie I, Oudit GY, Kaul P, Dyck JR, Anderson T; Alberta HEART Investigators.

ESC Heart Fail. 2018 Feb;5(1):19-26. doi: 10.1002/ehf2.12200. Epub 2017 Jul 25.

23.

Hospitalization for Recently Diagnosed Versus Worsening Chronic Heart Failure: From the ASCEND-HF Trial.

Greene SJ, Hernandez AF, Dunning A, Ambrosy AP, Armstrong PW, Butler J, Cerbin LP, Coles A, Ezekowitz JA, Metra M, Starling RC, Teerlink JR, Voors AA, O'Connor CM, Mentz RJ.

J Am Coll Cardiol. 2017 Jun 27;69(25):3029-3039. doi: 10.1016/j.jacc.2017.04.043.

PMID:
28641792
24.

A network analysis to compare biomarker profiles in patients with and without diabetes mellitus in acute heart failure.

Sharma A, Demissei BG, Tromp J, Hillege HL, Cleland JG, O'Connor CM, Metra M, Ponikowski P, Teerlink JR, Davison BA, Givertz MM, Bloomfield DM, Dittrich H, van Veldhuisen DJ, Cotter G, Ezekowitz JA, Khan MAF, Voors AA.

Eur J Heart Fail. 2017 Oct;19(10):1310-1320. doi: 10.1002/ejhf.912. Epub 2017 Jun 21.

25.

Multitype Events and the Analysis of Heart Failure Readmissions: Illustration of a New Modeling Approach and Comparison With Familiar Composite End Points.

Brown PM, Ezekowitz JA.

Circ Cardiovasc Qual Outcomes. 2017 Jun;10(6). pii: e003382. doi: 10.1161/CIRCOUTCOMES.116.003382.

26.

Characterization of hemodynamically stable acute heart failure patients requiring a critical care unit admission: Derivation, validation, and refinement of a risk score.

Raslan IR, Brown P, Westerhout CM, Ezekowitz JA, Hernandez AF, Starling RC, O'Connor C, McAlister FA, Rowe BH, Armstrong PW, van Diepen S.

Am Heart J. 2017 Jun;188:127-135. doi: 10.1016/j.ahj.2017.03.014. Epub 2017 Mar 25.

PMID:
28577668
27.

Association Between Diabetes During Pregnancy and Peripartum Cardiomyopathy: A Population-Level Analysis of 309,825 Women.

Dhesi S, Savu A, Ezekowitz JA, Kaul P.

Can J Cardiol. 2017 Jul;33(7):911-917. doi: 10.1016/j.cjca.2017.02.008. Epub 2017 Feb 24.

PMID:
28552180
28.

Navigating Choices Among a Sea of Comorbidities.

Armstrong PW, Ezekowitz JA.

J Am Coll Cardiol. 2017 May 16;69(19):2380-2382. doi: 10.1016/j.jacc.2017.03.022. No abstract available.

29.

Biased ligand of the angiotensin II type 1 receptor in patients with acute heart failure: a randomized, double-blind, placebo-controlled, phase IIB, dose ranging trial (BLAST-AHF).

Pang PS, Butler J, Collins SP, Cotter G, Davison BA, Ezekowitz JA, Filippatos G, Levy PD, Metra M, Ponikowski P, Teerlink JR, Voors AA, Bharucha D, Goin K, Soergel DG, Felker GM.

Eur Heart J. 2017 Aug 7;38(30):2364-2373. doi: 10.1093/eurheartj/ehx196.

PMID:
28459958
30.

Impact of Current Versus Previous Cardiac Resynchronization Therapy Guidelines on the Proportion of Patients With Heart Failure Eligible for Therapy.

Lyons KJ, Ezekowitz JA, Liang L, Heidenreich PA, Yancy CW, DeVore AD, Hernandez AF, Fonarow GC.

JACC Heart Fail. 2017 May;5(5):388-392. doi: 10.1016/j.jchf.2017.02.018. Review.

31.
32.

Dietary Self-management in Heart Failure: High Tech or High Touch?

Colin-Ramirez E, Arcand J, Ezekowitz JA.

Curr Treat Options Cardiovasc Med. 2017 Mar;19(3):19. doi: 10.1007/s11936-017-0515-9. Review.

PMID:
28299612
33.
34.

Composite End Points in Clinical Trials of Heart Failure Therapy: How Do We Measure the Effect Size?

Brown PM, Ezekowitz JA.

Circ Heart Fail. 2017 Jan;10(1). pii: e003222. doi: 10.1161/CIRCHEARTFAILURE.116.003222.

35.

Diabetes and heart failure in the crosshairs: where is the target?

Ezekowitz JA, Armstrong PW.

Eur J Heart Fail. 2017 Jan;19(1):66-68. doi: 10.1002/ejhf.703. No abstract available.

36.

Body Weight Change During and After Hospitalization for Acute Heart Failure: Patient Characteristics, Markers of Congestion, and Outcomes: Findings From the ASCEND-HF Trial.

Ambrosy AP, Cerbin LP, Armstrong PW, Butler J, Coles A, DeVore AD, Dunlap ME, Ezekowitz JA, Felker GM, Fudim M, Greene SJ, Hernandez AF, O'Connor CM, Schulte P, Starling RC, Teerlink JR, Voors AA, Mentz RJ.

JACC Heart Fail. 2017 Jan;5(1):1-13. doi: 10.1016/j.jchf.2016.09.012.

37.

The Impact and Implications of Twitter for Cardiovascular Medicine.

Gouda P, Das D, Clark A, Ezekowitz JA.

J Card Fail. 2017 Mar;23(3):266-267. doi: 10.1016/j.cardfail.2016.12.005. Epub 2016 Dec 21. No abstract available.

PMID:
28010999
38.

2016 AHA/ACC Clinical Performance and Quality Measures for Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures.

Al-Khatib SM, Yancy CW, Solis P, Becker L, Benjamin EJ, Carrillo RG, Ezekowitz JA, Fonarow GC, Kantharia BK, Kleinman M, Nichol G, Varosy PD.

J Am Coll Cardiol. 2017 Feb 14;69(6):712-744. doi: 10.1016/j.jacc.2016.09.933. Epub 2016 Dec 19. No abstract available.

39.

2016 AHA/ACC Clinical Performance and Quality Measures for Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures.

Al-Khatib SM, Yancy CW, Solis P, Becker L, Benjamin EJ, Carrillo RG, Ezekowitz JA, Fonarow GC, Kantharia BK, Kleinman M, Nichol G, Varosy PD.

Circ Cardiovasc Qual Outcomes. 2017 Jan;10(1):e000022. doi: 10.1161/HCQ.0000000000000022. Epub 2016 Dec 19. No abstract available.

40.

Interprovincial Differences in Canadian Coronary Care Unit Resource Use and Outcomes.

van Diepen S, Lin M, Ezekowitz JA, McAlister FA, Lee DS, Goodman SG, Armstrong PW, Kaul P.

Can J Cardiol. 2017 Jan;33(1):166-169. doi: 10.1016/j.cjca.2016.10.009. Epub 2016 Oct 19.

PMID:
27914806
41.

Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial.

Teerlink JR, Felker GM, McMurray JJ, Solomon SD, Adams KF Jr, Cleland JG, Ezekowitz JA, Goudev A, Macdonald P, Metra M, Mitrovic V, Ponikowski P, Serpytis P, Spinar J, Tomcsányi J, Vandekerckhove HJ, Voors AA, Monsalvo ML, Johnston J, Malik FI, Honarpour N; COSMIC-HF Investigators.

Lancet. 2016 Dec 10;388(10062):2895-2903. doi: 10.1016/S0140-6736(16)32049-9. Epub 2016 Dec 1.

42.

Multidisciplinary Approach to Novel Therapies in Cardio-Oncology Research (MANTICORE 101-Breast): A Randomized Trial for the Prevention of Trastuzumab-Associated Cardiotoxicity.

Pituskin E, Mackey JR, Koshman S, Jassal D, Pitz M, Haykowsky MJ, Pagano JJ, Chow K, Thompson RB, Vos LJ, Ghosh S, Oudit GY, Ezekowitz JA, Paterson DI.

J Clin Oncol. 2017 Mar 10;35(8):870-877. doi: 10.1200/JCO.2016.68.7830. Epub 2016 Nov 28.

PMID:
27893331
43.

Hyperkalemia, Sacubitril/Valsartan, and Mineralocorticoid Antagonists in Patients With Heart Failure.

Ezekowitz JA.

JAMA Cardiol. 2017 Jan 1;2(1):86-87. doi: 10.1001/jamacardio.2016.4731. No abstract available.

PMID:
27842180
44.

Composite End Points in Acute Heart Failure Research: Data Simulations Illustrate the Limitations.

Brown PM, Anstrom KJ, Felker GM, Ezekowitz JA.

Can J Cardiol. 2016 Nov;32(11):1356.e21-1356.e28. doi: 10.1016/j.cjca.2016.02.067. Epub 2016 Mar 3.

PMID:
27499377
45.

The current and future financial burden of hospital admissions for heart failure in Canada: a cost analysis.

Tran DT, Ohinmaa A, Thanh NX, Howlett JG, Ezekowitz JA, McAlister FA, Kaul P.

CMAJ Open. 2016 Jul 21;4(3):E365-E370. eCollection 2016 Jul-Sep.

46.

Heterogeneity across one disease, two drugs, three trials, and four guidelines: are we further ahead?

Ezekowitz JA, Sepehrvand N.

Eur J Heart Fail. 2016 Oct;18(10):1244-1247. doi: 10.1002/ejhf.651. No abstract available.

47.

Influence of Clinical Trial Site Enrollment on Patient Characteristics, Protocol Completion, and End Points: Insights From the ASCEND-HF Trial (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure).

Greene SJ, Hernandez AF, Sun JL, Metra M, Butler J, Ambrosy AP, Ezekowitz JA, Starling RC, Teerlink JR, Schulte PJ, Voors AA, Armstrong PW, O'Connor CM, Mentz RJ.

Circ Heart Fail. 2016 Sep;9(9). pii: e002986. doi: 10.1161/CIRCHEARTFAILURE.116.002986.

48.

Early Follow-Up After a Heart Failure Exacerbation: The Importance of Continuity.

McAlister FA, Youngson E, Kaul P, Ezekowitz JA.

Circ Heart Fail. 2016 Sep;9(9). pii: e003194. doi: 10.1161/CIRCHEARTFAILURE.116.003194.

49.

Apixaban 5 mg Twice Daily and Clinical Outcomes in Patients With Atrial Fibrillation and Advanced Age, Low Body Weight, or High Creatinine: A Secondary Analysis of a Randomized Clinical Trial.

Alexander JH, Andersson U, Lopes RD, Hijazi Z, Hohnloser SH, Ezekowitz JA, Halvorsen S, Hanna M, Commerford P, Ruzyllo W, Huber K, Al-Khatib SM, Granger CB, Wallentin L; Apixaban for Reduction of Stroke and Other Thromboembolic Complications in Atrial Fibrillation (ARISTOTLE) Investigators.

JAMA Cardiol. 2016 Sep 1;1(6):673-81. doi: 10.1001/jamacardio.2016.1829.

PMID:
27463942
50.

Cost Effectiveness of Eplerenone for the Treatment of Systolic Heart Failure with Mild Symptoms in Alberta, Canada.

Thanh NX, Ezekowitz JA, Tran DT, Kaul P.

Am J Cardiovasc Drugs. 2016 Oct;16(5):365-76. doi: 10.1007/s40256-016-0177-0.

PMID:
27300508

Supplemental Content

Loading ...
Support Center